专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

CN102712927A 通过抑制膜结合转录因子肽酶，位点1(MBTPS1)的天然反义转录物来治疗MBTPS1相关疾病失效复审申请
公开(公告)号：CN102712927A
公开(公告)日：2012-10-03
申请号：CN201080056319.6
申请日：2010-12-15
申请人：库尔纳公司
发明人： J·克拉德 , O·霍克瓦舍曼
IPC分类号： C12N15/113 , C12N15/57 , C12N9/48 , A61K48/00 , A61K31/7088
CPC分类号： C12N15/1137 , A61K31/7088 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/113 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12Y304/21112 , Y10T436/143333 , C12N2310/3521 , C12N2310/3525
摘要：本发明涉及调节膜结合转录因子肽酶，位点1(MBTPS1)的表达和/或功能的反义寡核苷酸，尤其是，通过靶向膜结合转录因子肽酶，位点1(MBTPS1)的天然反义多核苷酸。本发明还涉及这些反义寡核苷酸的鉴定和它们在治疗与MBTPS1表达相关的疾病和病症中的用途。

2. 发明公开

CN106661556A 烟草蛋白酶基因无效
公开(公告)号：CN106661556A
公开(公告)日：2017-05-10
申请号：CN201580038165.0
申请日：2015-07-16
申请人：菲利普莫里斯产品有限公司
发明人： L·博韦 , D·弗洛拉克 , J·巴蒂
IPC分类号： C12N5/10 , C12N15/82 , A01H5/12
CPC分类号： A24B3/12 , A01H5/12 , C12N9/1029 , C12N9/104 , C12N9/48 , C12N9/63 , C12N15/8201 , C12N15/8213 , C12N15/8242 , C12N15/8261 , C12Y203/01091 , C12Y203/02002 , C12Y304/21107 , C12Y304/21112 , C12Y304/22 , C12Y304/22002 , C12Y304/23 , C12Y304/24 , Y02A40/146
摘要：本发明提供蛋白酶基因，其在烟草植物材料的烘烤期间以特定方式经调节且其影响烘烤的烟草的风味。

3. 发明授权

CN102712927B 通过抑制膜结合转录因子肽酶，位点1(MBTPS1)的天然反义转录物来治疗MBTPS1相关疾病失效复审申请
公开(公告)号：CN102712927B
公开(公告)日：2017-12-01
申请号：CN201080056319.6
申请日：2010-12-15
申请人：库尔纳公司
发明人： J·克拉德 , O·霍克瓦舍曼
IPC分类号： C12N15/113 , C12N15/57 , C12N9/48 , A61K48/00 , A61K31/7088
CPC分类号： C12N15/1137 , A61K31/7088 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/113 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12Y304/21112 , Y10T436/143333 , C12N2310/3521 , C12N2310/3525
摘要：本发明涉及调节膜结合转录因子肽酶，位点1(MBTPS1)的表达和/或功能的反义寡核苷酸，尤其是，通过靶向膜结合转录因子肽酶，位点1(MBTPS1)的天然反义多核苷酸。本发明还涉及这些反义寡核苷酸的鉴定和它们在治疗与MBTPS1表达相关的疾病和病症中的用途。

4. 发明公开

CN104011204A 枯草杆菌酶变体和编码它们的多核苷酸无效复审申请
公开(公告)号：CN104011204A
公开(公告)日：2014-08-27
申请号：CN201280063467.X
申请日：2012-12-18
申请人：诺维信公司
发明人： W.贝森马特 , A.本尼 , E.P.弗里斯 , P.O.米奇尔森
IPC分类号： C12N9/54
CPC分类号： C12N9/50 , C11D3/386 , C11D3/38609 , C11D3/38618 , C11D3/38681 , C12N9/54 , C12Y304/21 , C12Y304/21062 , C12Y304/21112
摘要：本发明涉及多种蛋白酶变体以及用于获得蛋白酶变体的多种方法。本发明还涉及编码这些变体的多核苷酸；包含这些多核苷酸的核酸构建体、载体、以及宿主细胞；以及使用这些变体的方法。

5. 发明授权

US09879264B2 Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 有权
公开(公告)号：US09879264B2
公开(公告)日：2018-01-30
申请号：US14857259
申请日：2015-09-17
申请人： CuRNA, Inc.
发明人： Joseph Collard , Olga Khorkova Sherman
IPC分类号： C12N15/113 , A61K31/713 , A61K31/7088
CPC分类号： C12N15/1137 , A61K31/7088 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/113 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12Y304/21112 , Y10T436/143333 , C12N2310/3521 , C12N2310/3525
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.

6. 发明申请

US20160002640A1 TREATMENT OF MEMBRANE BOUND TRANSCRIPTION FACTOR PEPTIDASE, SITE 1 (MBTPS1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO MBTPS1 有权
标题翻译：通过抑制自然抗原转录物到MBTPS1的相关疾病治疗膜结合转录因子蛋白酶，位点1（MBTPS1）的相关疾病
公开(公告)号：US20160002640A1
公开(公告)日：2016-01-07
申请号：US14857259
申请日：2015-09-17
申请人： CuRNA, Inc.
发明人： Joseph COLLARD , Olga Khorkova Sherman
IPC分类号： C12N15/113 , A61K31/713
CPC分类号： C12N15/1137 , A61K31/7088 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/113 , C12N2310/313 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12Y304/21112 , Y10T436/143333 , C12N2310/3521 , C12N2310/3525
摘要： The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1), in particular, by targeting natural antisense polynucleotides of Membrane Bound Transcription Factor Peptidase, site 1 (MBTPS1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MBTPS1.
摘要翻译：本发明涉及通过靶向膜结合转录因子肽酶（位点1（MBTPS1））的天然反义多核苷酸来调节膜结合转录因子肽酶，位点1（MBTPS1）的表达和/或功能的反义寡核苷酸。本发明还涉及这些反义寡核苷酸的鉴定及其在治疗与MBTPS1表达相关的疾病和病症中的用途。

7. 发明授权

US09493774B2 Inhibition of PCSK9 through RNAi 有权
标题翻译：通过RNAi抑制PCSK9
公开(公告)号：US09493774B2
公开(公告)日：2016-11-15
申请号：US13143275
申请日：2010-01-05
申请人： Joanne Kamens , Anastasia Khvorova
发明人： Joanne Kamens , Anastasia Khvorova
IPC分类号： C12N15/85 , C07H21/02 , C07H21/04 , C12N15/113
CPC分类号： C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/3515 , C12N2310/531 , C12N2320/11 , C12Y304/21061 , C12Y304/21112 , C12N2310/3521 , C12N2310/3533
摘要： The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2′-O-methyl groups at the 2nd 5′-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
摘要翻译：本发明涉及具有基因沉默活性的各种PCSK9 RNAi构建体及其应用。该构建体具有19-49个核苷酸，优选25,26或27个核苷酸的双链区域，并且优选是平端的。该构建体具有选择性的最小修饰以赋予生物活性，毒性，稳定性和靶基因特异性的最佳平衡。可以修饰正义链，使得构建体不被切丝酶或其它RNA酶III切割，并且反义链的整个长度被加载到RISC中。此外，反义链也可以在第二个5'-末端核苷酸被2'-O-甲基修饰，以大大减少脱靶沉默。本发明的构建体大大避免了哺乳动物细胞中的干扰素反应和序列无关的凋亡，表现出更好的血清稳定性和增强的靶特异性。

8. 发明申请

US20100216864A1 RNA Antagonist Compounds for the Modulation of PCSK9 审中-公开
标题翻译：用于调节PCSK9的RNA拮抗剂化合物
公开(公告)号：US20100216864A1
公开(公告)日：2010-08-26
申请号：US12444806
申请日：2007-10-09
申请人： Ellen Marie Straarup , Niels Fisker Nielsen
发明人： Ellen Marie Straarup , Niels Fisker Nielsen
IPC分类号： A61K31/7052 , C12N15/52 , C12N5/07 , A61P3/04 , A61P3/10
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/14 , C12Y304/21112
摘要： The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed.
摘要翻译：本发明提供了调节PCSK9表达的化合物，组合物和方法。特别地，本发明涉及可与编码PCSK9的靶核酸杂交的低聚化合物，例如寡核苷酸化合物，以及制备这种寡聚化合物的方法。已显示寡核苷酸化合物调节PCSK9的表达，并且其药物制剂及其作为治疗高胆固醇血症和相关疾病的用途被公开。

9. 发明公开

EP2076597A2 RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF PCSK9 审中-公开
标题翻译： RNA拮抗剂化合物FOR PCSK9的调制
公开(公告)号：EP2076597A2
公开(公告)日：2009-07-08
申请号：EP07821072.1
申请日：2007-10-09
申请人： Santaris Pharma A/S
发明人： STRAARUP, Ellen Marie , NIELSEN, Niels Fisher
IPC分类号： C12N15/11
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/14 , C12Y304/21112
摘要： The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed.

10. 发明公开

EP2444494A1 RNA antagonist compounds for the modulation of PCSK9 有权
标题翻译： RNA-ANTAGONISTENVERBINDUNGEN ZUR MODULATION VON PCSK9
公开(公告)号：EP2444494A1
公开(公告)日：2012-04-25
申请号：EP11181596.5
申请日：2007-10-09
申请人： Santaris Pharma A/S
发明人： Straarup, Ellen Marie , Nielsen, Niels Fisker
IPC分类号： C12N15/113
CPC分类号： C12N15/1137 , C12N2310/11 , C12N2310/14 , C12Y304/21112
摘要： The present invention provides compounds, compositions and methods for modulating the expression of PCSK9. In particular, this invention relates to oligomeric compounds, such as oligonucleotide compounds, which are hybridisable with target nucleic acids encoding PCSK9, and methods for the preparation of such oligomeric compounds. The oligonucleotide compounds have been shown to modulate the expression of PCSK9, and pharmaceutical preparations thereof and their use as treatment of hypercholesterolemia and related disorders are disclosed.
摘要翻译：本发明提供了调节PCSK9表达的化合物，组合物和方法。特别地，本发明涉及可与编码PCSK9的靶核酸杂交的低聚化合物，例如寡核苷酸化合物，以及制备这种寡聚化合物的方法。已显示寡核苷酸化合物调节PCSK9的表达及其药物制剂及其作为治疗高胆固醇血症和相关疾病的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式